Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Oct 10, 2024Closes
Oct 14, 2026Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Education, Health
Eligible applicants: Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Small businesses, State governments, Others (see text field entitled "Additional Information on Eligibility" for clarification), Native American tribal organizations (other than Federally recognized tribal governments), Private institutions of higher education, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Independent school districts, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, City or township governments, Special district governments, County governments, Public housing authorities/Indian housing authorities, For profit organizations other than small businesses
Description
Through this Notice of Funding Opportunity (NOFO) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this NOFO is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" r "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this NOFO encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.